AstraZeneca Pharma India Reports Strong Revenue Growth Amid Profit Dip

Revenue from operations: ₹682.79 crore (₹68,279 lakh)
Profit after tax: ₹37.93 crore (₹3,793 lakh)

Reader Takeaway: Strong revenue growth driven by core segments, but declining profit and a significant contingent liability pose challenges.

What just happened

AstraZeneca Pharma India announced its financial results for the quarter ending June 30, 2026. The company achieved a significant 30% year-on-year increase in revenue from operations, reaching ₹682.79 crore. This growth was primarily attributed to strong performance in its key therapy areas.

Why this matters

While the top-line growth is positive, the company's profit after tax saw a year-on-year decrease of 32%, falling to ₹37.93 crore from ₹55.83 crore in the same quarter last year. This divergence between revenue and profit growth highlights potential pressure on margins or increased operating costs. Investors will be watching the reasons behind this profitability squeeze.

The backstory

For the quarter ended June 30, 2025, AstraZeneca Pharma India had reported revenue of ₹526.31 crore and a profit after tax of ₹55.83 crore. The current results show a strong recovery in revenue but a notable drop in profitability compared to the previous year's performance.

What changes now

The company has disclosed a significant contingent liability of ₹148.66 crore related to an order from the National Pharmaceutical Pricing Authority (NPPA). This order concerns alleged overcharging for a respiratory drug. Management is contesting this order. Additionally, the board has approved leadership changes, with Mr. Arun Krishna appointed as Additional Director and Ms. Bhavana Agrawal transitioning to Non-Executive Director.

Risks to watch

The primary risk highlighted is the contingent liability of ₹148.66 crore from the NPPA. A definitive adverse outcome could lead to substantial financial implications. Investors should also monitor the strategic implications of the manufacturing site exit and leadership transitions.

Peer comparison

(No peer comparison data available in the filing)

Context metrics (time-bound)

• Revenue from operations for the quarter ended June 30, 2026: ₹682.79 crore (up 30% YoY).
• Profit after tax for the quarter ended June 30, 2026: ₹37.93 crore (down 32% YoY).
• EPS for the quarter ended June 30, 2026: ₹15.17 (down 32% YoY).
• Contingent liability disclosed: ₹148.66 crore.

What to track next

Investors should closely follow the outcome of the legal challenge against the NPPA order and any further updates on the company's strategic initiatives, including the manufacturing site exit and leadership roles.